Skip to content

BCBS Michigan

Does BCBS Michigan cover Wegovy?

Yes. BCBS Michigan covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult - Obesity or Overweight with Comorbidity (Standard Pathway)

All of:

  • Physician attestation of BMI ≥ 30 kg/m2 (obese) OR BMI ≥ 27 kg/m2 (overweight) with at least one weight-related comorbidity (hypertension, T2DM, or dyslipidemia)
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Adult - Alternative High-BMI Pathway via Teladoc Program

All of:

  • Age ≥ 18 years old
  • BMI ≥ 35 kg/m2
  • Documentation of current (within 30 days) baseline weight
  • Documentation of active participation for a minimum of 6 months in a lifestyle modification program (e.g., food diaries documenting caloric deficit or adherence to low calorie/modified diet, OR exercise logs/step counter reports/gym attendance logs/app/fitness tracker showing at least 10,000 steps/day or 150 min/week moderate-intensity activity)
  • Documentation of current active participation in Teladoc Health Weight Management Program
  • Must be prescribed by a PCP or provider with an established relationship with the member, who has seen the member in-person for evaluation and management of overall health

Pediatric - Ages 12 to 17

All of:

  • Age 12 to 17 years
  • BMI ≥ 95th percentile standardized for age and sex
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Physician attestation of BMI (≥ 30 kg/m2 for obesity, or ≥ 27 kg/m2 with comorbidity, or ≥ 35 kg/m2 for alternative pathway)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (healthy eating, exercise if appropriate)
  • For alternative adult pathway: Documentation of at least 6 months of active participation in a lifestyle modification program (food diaries, exercise logs, step counter reports, gym logs, fitness tracker printouts showing 10,000 steps/day or 150 min/week moderate-intensity activity)
  • For alternative adult pathway: Documentation of current active participation in Teladoc Health Weight Management Program
  • For alternative adult pathway: Confirmation that prescriber is a PCP or established-relationship provider who has seen member in-person
  • For pediatric: Documentation that BMI is ≥ 95th percentile standardized for age and sex
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation (adults): Physician attestation that member maintains ≥ 5% weight loss from baseline
  • For continuation (adults): Current weight submission
  • For continuation (adults): Attestation of continued active participation in lifestyle modifications
  • For continuation (adults): BMI ≥ 18.5 kg/m2
  • For continuation (pediatrics): Physician attestation that member maintains ≥ 1% reduction in BMI from baseline
  • For continuation (pediatrics): Current weight submission
  • For continuation (pediatrics): Attestation of continued active participation in lifestyle modifications
  • For continuation (pediatrics): BMI-for-age percentile ≥ 5th percentile

Approval and renewal

  • Initial approval: 12 months
  • Renewal: At least 5% weight loss from the starting weight.
  • Renewal: At least 1% reduction in BMI.
  • Renewal: For adults (obesity/overweight pathway): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI ≥ 18.5 kg/m2. For pediatrics (ages 12-17): 1% reduction in BMI from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI-for-age percentile ≥ 5th percentile. Initial BMI/comorbidity and other initial criteria are not explicitly re-verified at continuation.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The document header states 'NC' (Not Covered) notation appears next to Wegovy and references that coverage criteria is 'determined by group benefit.' This suggests coverage is group-specific and not universally covered under all plans. The NC designation on the document header may indicate it is not covered for all members. Multiple qualification pathways exist including an alternative high-BMI pathway requiring Teladoc Health Weight Management Program participation. The document title states 'March 2019' but the revised date is 06-01-2026, indicating the effective date is June 2026.

Policy effective June 1, 2026 · verified June 2, 2026 · source: Prior Authorization And Step Therapy Guidelines · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Adults with Established CVD and Obesity/Overweight

All of:

  • Established cardiovascular disease
  • Obesity (BMI ≥ 30 kg/m2) OR overweight (BMI ≥ 27 kg/m2)
  • Used in combination with reduced calorie diet and increased physical activity
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of established cardiovascular disease
  • Physician attestation of BMI ≥ 30 kg/m2 (obese) or ≥ 27 kg/m2 (overweight)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation that member maintains ≥ 5% weight loss from baseline
  • For continuation: Current weight submission
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI ≥ 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • Renewal: At least 5% weight loss from the starting weight.
  • Renewal: For adults (obesity/CV risk reduction): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI ≥ 18.5 kg/m2. CV disease establishment and other initial criteria are not explicitly re-verified at continuation.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The CV risk reduction pathway is explicitly listed as a separate qualification route for adults with established cardiovascular disease. The policy does not specify particular CV qualifying events (e.g., MI, stroke, PAD) beyond 'established cardiovascular disease.' No exclusion of patients with diabetes is stated. Continuation uses the same criteria as the obesity/overweight continuation pathway (5% weight loss from baseline).

Policy effective June 1, 2026 · verified June 2, 2026 · source: Prior Authorization And Step Therapy Guidelines · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with Moderate to Advanced Liver Fibrosis (F2-F3)

All of:

  • Diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with stages F2 to F3
  • Adult (age ≥ 18 years old)
  • Current baseline weight documented
  • Used in combination with reduced calorie diet and increased physical activity
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation of current weight submitted to plan
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI ≥ 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • Renewal: For MASH continuation: Physician attestation of current weight submitted to plan, attestation of continued active participation in lifestyle modifications that support weight loss, BMI ≥ 18.5 kg/m2. No explicit weight loss percentage threshold required for MASH continuation (unlike obesity/CV pathways which require 5% weight loss).

Not covered when

  • Cirrhotic MASH is excluded (noncirrhotic only)
  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The policy specifies noncirrhotic MASH only, with fibrosis stages F2 to F3. No specific fibrosis confirmation methods (biopsy, FibroScan, FIB-4, MRE, ELF) are specified in the policy. No lookback periods for diagnostic tests are specified. Continuation criteria for MASH differ from obesity/CV pathways — no explicit weight loss percentage threshold is required; instead physician attestation of current weight and continued lifestyle modifications are required along with BMI ≥ 18.5 kg/m2.

Policy effective June 1, 2026 · verified June 2, 2026 · source: Prior Authorization And Step Therapy Guidelines · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Michigan cover Wegovy?
Yes. BCBS Michigan covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with BCBS Michigan?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months.
What does BCBS Michigan require to renew Wegovy?
Weight Loss — Applies to Employer and ACA Marketplace plans. At least 5% weight loss from the starting weight. At least 1% reduction in BMI. For adults (obesity/overweight pathway): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI ≥ 18.5 kg/m2. For pediatrics (ages 12-17): 1% reduction in BMI from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI-for-age percentile ≥ 5th percentile. Initial BMI/comorbidity and other initial criteria are not explicitly re-verified at continuation. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. At least 5% weight loss from the starting weight. For adults (obesity/CV risk reduction): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI ≥ 18.5 kg/m2. CV disease establishment and other initial criteria are not explicitly re-verified at continuation. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. For MASH continuation: Physician attestation of current weight submitted to plan, attestation of continued active participation in lifestyle modifications that support weight loss, BMI ≥ 18.5 kg/m2. No explicit weight loss percentage threshold required for MASH continuation (unlike obesity/CV pathways which require 5% weight loss).
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Michigan: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Michigan Medicaid, Molina Healthcare, Priority Health, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts

All insurance plans · All medications

Summary of BCBS Michigan's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.